Form 4: Avanos Medical Director Receives Restricted Share Units

Avanos Medical, Inc. reports that Director Gary Blackford was issued 12,003 restricted share units on May 8, 2026, replacing prior units.

Summary

• Gary Blackford, a Director at Avanos Medical, Inc., was granted 12,003 restricted share units (RSUs) on May 8, 2026.
• These RSUs represent a contingent right to receive a cash payment equivalent to the value of one share of Avanos Medical's common stock.
• The issuance of these RSUs replaces previously issued restricted share units granted on January 2, 2025.
• The RSUs will vest upon the Reporting Person's termination of service on the Issuer's Board of Directors.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details a routine compensation adjustment for a director rather than significant financial performance or strategic shifts.

Positives

• Director compensation through equity awards like RSUs can align management interests with shareholder value.
• The replacement of existing RSUs suggests a continuation of incentive programs for key personnel.

Negatives

• The filing does not provide details on the valuation or potential future value of the RSUs.
• The vesting condition tied to termination of service could be viewed as a retention incentive, but also implies a future departure.

Risks

• The value of the restricted share units is subject to the future performance and stock price of Avanos Medical, Inc.
• There is a risk that the RSUs may not vest if the Reporting Person does not meet the service termination condition.

Future Outlook

The future outlook for the restricted share units is dependent on the vesting schedule and the future stock price performance of Avanos Medical, Inc.

Industry Context

StockSavvy.ai notes that the issuance of restricted share units to directors is a common practice in the healthcare and medical technology sector to incentivize long-term performance and align executive interests with shareholders.

Stakeholder Impact

• Shareholders: The issuance of RSUs is a form of compensation that impacts equity dilution, though the replacement of existing units may not represent new dilution.
• Employees: This filing is specific to director compensation and does not directly impact general employees.
• Management: The RSUs serve as an incentive for the director to remain with the company and contribute to its success.

Next Steps

• The restricted share units will vest upon the Reporting Person's termination of service on the Issuer's Board of Directors.
• The cash payment equivalent to the value of Avanos Medical's common stock will be made upon vesting.

Key Dates

Keywords

Avanos Medical, AVNS, Form 4, Insider Trading, Restricted Share Units, RSU, Director Compensation, Beneficial Ownership, SEC Filing, Equity Awards